Loading
Cancer Treatment and Pharmacology / HER2/EGFR in Cancer Research · Journal article
Journal of Clinical Oncology · September 11, 2026
Well-designed and adequately powered for the question it asks.
This Phase 3 randomized trial demonstrates that trastuzumab botidotin significantly prolongs progression-free survival compared to trastuzumab emtansine in HER2-positive advanced breast cancer previously treated with trastuzumab and taxane (median 11.1 vs 4.4 months; HR 0.39; p<.0001). The benefit is consistent across key subgroups, objective response rate is higher, and the safety profile is distinct with notable ocular toxicity offset by lower pulmonary, hematologic, hepatic, and GI toxicity; overall survival data remain immature.
Phase 3, open-label, multicenter, randomized controlled trial. Adult patients with HER2-positive, unresectable/metastatic breast cancer who had received prior trastuzumab and a taxane. Intervention: Trastuzumab botidotin. Compared with: Trastuzumab emtansine. n = 365. 57 centers in China.
Median PFS 11.1 months (trastuzumab botidotin) vs 4.4 months (trastuzumab emtansine) Hazard ratio 0.39 (95% CI 0.30 to 0.51); nominal P <.0001 Objective response rate 76.9% (95% CI 70.1 to 82.8) vs 53.0% (95% CI 45.5 to 60.4)
Source does not report incidence or severity grades for specific ocular adverse events, details of recovery protocols, or long-term follow-up data Grade ≥3 treatment-emergent adverse events: 69.8% (trastuzumab botidotin) vs 63.7% (trastuzumab emtansine)
For clinicians treating trastuzumab- and taxane-pretreated HER2-positive advanced breast cancer, trastuzumab botidotin offers a substantially longer PFS with a higher response rate than trastuzumab emtansine. The distinct safety profile (notably high ocular toxicity but lower organ-system toxicities) requires patient counseling and ophthalmologic monitoring; OS benefit remains to be established.
Phase 3 RCT with rigorous design (BICR-assessed primary endpoint, blinded review, 1:1 randomization) showing statistically significant and clinically meaningful PFS improvement (HR 0.39, p<.0001) meeting prespecified superiority boundary, though OS remains immature.
As stated by the source record.
Quoted from the source exactly as published.
For clinicians treating trastuzumab- and taxane-pretreated HER2-positive advanced breast cancer, trastuzumab botidotin offers a substantially longer PFS with a higher response rate than trastuzumab emtansine. The distinct safety profile (notably high ocular toxicity but lower organ-system toxicities) requires patient counseling and ophthalmologic monitoring; OS benefit remains to be established.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
PURPOSE To evaluate the safety and efficacy of the novel human epidermal growth factor receptor 2 (HER2)–directed antibody-drug conjugate, trastuzumab botidotin, for the treatment of HER2-positive unresectable/metastatic breast cancer (BC). METHODS In this phase III, open-label, multicenter trial (ClinicalTrials.gov identifier: NCT06968585 ), conducted at 57 centers in China, adult patients with HER2-positive, unresectable/metastatic BC who had received prior trastuzumab and a taxane were randomly assigned (1:1) to receive trastuzumab botidotin or trastuzumab emtansine. The primary end point was progression-free survival (PFS), assessed by blinded independent central review (BICR), using an intention-to-treat analysis. In a prespecified interim analysis of PFS per BICR, trastuzumab botidotin met the prespecified superiority boundary ( P <.0001). We report here the prespecified final analysis of PFS. RESULTS Between July 18, 2023, and April 26, 2024, 365 patients were randomly assigned to trastuzumab botidotin (n = 182) or trastuzumab emtansine (n = 183). At data cutoff (median follow-up, 14.9 months), trastuzumab botidotin resulted in longer PFS than trastuzumab emtansine (median, 11.1 v 4.4 months; hazard ratio [HR], 0.39 [95% CI, 0.30 to 0.51]; nominal P <.0001). Benefit was consistent across subgroups, including those defined by prior lines of anti-HER2 therapy, prior pertuzumab or anti-HER2 tyrosine kinase inhibitors, and visceral metastases. The objective response rate was 76.9% (95% CI, 70.1 to 82.8) with trastuzumab botidotin and 53.0% (95% CI, 45.5 to 60.4) with trastuzumab emtansine. Overall survival data were immature (medians not reached in either group; HR, 0.62 [95% CI, 0.38 to 1.03]). Grade ≥3 treatment-emergent adverse events occurred in 127 (69.8%) and 116 (63.7%) patients in each group, respectively. Ocular treatment-related adverse events had a high incidence with trastuzumab botidotin; however, with a protocol-defined algorithm, most events generally recovered or resolved. Trastuzumab botidotin treatment had low incidences of pulmonary, hematologic, hepatic, and GI toxicities. CONCLUSION Among patients with HER2-positive advanced BC previously treated with trastuzumab and a taxane, trastuzumab botidotin resulted in significantly longer PFS than trastuzumab emtansine, with a distinct safety profile.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.